# Irinotecan Plus Lenalidomide in Adult Patients With Recurrent Glioblastoma Multiforme: Phase I

> **NCT00671801** · PHASE1 · TERMINATED · sponsor: **M.D. Anderson Cancer Center** · enrollment: 24 (actual)

## Conditions studied

- Malignant Gliomas

## Interventions

- **DRUG:** Irinotecan
- **DRUG:** Lenalidomide

## Key facts

- **NCT ID:** NCT00671801
- **Lead sponsor:** M.D. Anderson Cancer Center
- **Sponsor class:** OTHER
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** TERMINATED
- **Start date:** 2008-04-29
- **Primary completion:** 2014-02
- **Final completion:** 2014-02
- **Target enrollment:** 24 (ACTUAL)
- **Why stopped:** Toxicity
- **Last updated:** 2018-11-13

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00671801

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00671801, "Irinotecan Plus Lenalidomide in Adult Patients With Recurrent Glioblastoma Multiforme: Phase I". Retrieved via AI Analytics 2026-06-23 from https://api.ai-analytics.org/clinical/NCT00671801. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*